TLR7 and neoplasm: In preclinical tumor models, intratumoral injection of a TLR2 agonist or targeted delivery of nanoparticles loaded with a TLR7/8 agonist have also been demonstrated to induce repolarization of TAMs towards an anti-tumor phenotype [84,85].